Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Free Report) insider Sarah Gheuens sold 500 shares of the stock in a transaction that occurred on Thursday, October 22nd. The stock was sold at an average price of $37.52, for a total value of $18,760.00. Following the transaction, the insider directly owned 54,645 shares of the company’s stock, valued at approximately $2,050,280.40. This trade represents a 0.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Sarah Gheuens also recently made the following trade(s):
- On Wednesday, October 21st, Sarah Gheuens sold 1,489 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $37.53, for a total value of $55,882.17.
- On Tuesday, August 4th, Sarah Gheuens sold 30,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $30.48, for a total transaction of $914,400.00.
Agios Pharmaceuticals Stock Down 0.5%
Agios Pharmaceuticals stock opened at $37.00 on Friday. Agios Pharmaceuticals, Inc. has a 52 week low of $22.24 and a 52 week high of $46.00. The firm’s 50-day simple moving average is $33.41 and its 200 day simple moving average is $32.79. The firm has a market capitalization of $2.21 billion, a PE ratio of -5.28 and a beta of 0.63.
Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.04). The company had revenue of $44.75 million for the quarter, compared to analyst estimates of $26.39 million. Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. On average, research analysts expect that Agios Pharmaceuticals, Inc. will post -5.83 EPS for the current fiscal year.
Analyst Ratings Changes
AGIO has been the subject of several research reports. Bank of America boosted their price objective on shares of Agios Pharmaceuticals from $46.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, September 21st. Royal Bank Of Canada boosted their price target on Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “sector perform” rating in a report on Tuesday, July 7th. HC Wainwright upped their price objective on Agios Pharmaceuticals from $52.00 to $55.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Monday, September 21st. Finally, Truist Financial reduced their price objective on shares of Agios Pharmaceuticals from $39.00 to $37.00 and set a “buy” rating for the company in a report on Wednesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Agios Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $41.50.
Read Our Latest Research Report on AGIO
Institutional Trading of Agios Pharmaceuticals
A number of hedge funds and other institutional investors have recently made changes to their positions in AGIO. Sei Investments Co. boosted its stake in shares of Agios Pharmaceuticals by 342.8% during the 1st quarter. Sei Investments Co. now owns 63,550 shares of the biopharmaceutical company’s stock worth $2,150,000 after acquiring an additional 49,198 shares in the last quarter. SCS Capital Management LLC acquired a new position in shares of Agios Pharmaceuticals in the 2nd quarter valued at about $22,743,000. Bank of America Corp DE acquired a new position in Agios Pharmaceuticals in the 2nd quarter valued at approximately $18,847,000. Parkman Healthcare Partners LLC purchased a new stake in shares of Agios Pharmaceuticals during the second quarter worth $24,828,000. Finally, Squarepoint Ops LLC raised its stake in shares of Agios Pharmaceuticals by 53.7% during the 2nd quarter. Squarepoint Ops LLC now owns 321,138 shares of the biopharmaceutical company’s stock worth $11,917,000 after purchasing an additional 112,250 shares in the last quarter.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company’s research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.
Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.
Featured Stories
- Five stocks we like better than Agios Pharmaceuticals
- Bloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline
- Why Western Digital’s AI Storage Boom Defies the Chip Sell-Off
- Grand Canyon Education Strengthens Its Outlook, But Wall Street Remains Divided
- Amex Stock Slides on Job Cuts, But the Real Story Is Macro
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
